NCT02235077
Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure
See it on ClinicalTrials.gov ↗360 people
35.8%
64.2%
129 womenmiddle line = equal numbers231 men
- Phase
- PHASE2
- Paid for by
- Duke University
- Finished
- 2016-06-06
- Health conditions
- Heart Failure
- Who could join
- Anyone
- Ages
- 21 Years – no maximum
- Average age
- mean 64.7 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- White 55.6% · Black / African American 41.9% · American Indian / Alaska Native 1.1% · Asian 1.1% · More than one race 0.3% · Native Hawaiian / Pacific Islander 0% · Not reported 0%
Women left out
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Severe liver disease (ALT or AST \>3 x normal, alkaline phosphatase or bilirubin \>2x normal)”
- No heart disease
Women with heart disease, heart rhythm problems or a past heart attack were turned away.
“Hemodynamically significant arrhythmias or defibrillator shock within 1 week”
- No cancer
Women with current or past cancer were turned away.
“Active malignancy other than non-melanoma skin cancers”
Study titles and rules are shown in their original English.